Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

Randomised, triple-masked, single-group dose-ranging study in healthy older adults (60–85 years) testing single oral doses of psilocybin across three level cohorts (1–10 mg; 11–20 mg; 21–30 mg). Outcomes compare baseline with one-week and one-month post-treatment.

Multimodal assessment includes anatomical MRI, diffusion-weighted imaging, fMRI, cognitive batteries, perceptual tasks, peripheral psychophysiology and surveys to evaluate persisting effects on brain structure, function, cognition, predictive coding and affect.